palbociclib vs placebo | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
death (overall survival) | no data | progression or death (progression free survival PFS) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
palbociclib + letrozole vs letrozole alone | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
death (overall survival) | no data | progression or death (progression free survival PFS) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
palbociclib + exemestane vs capecitabine | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
death (overall survival) | no data | progression or death (progression free survival PFS) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
palbociclib + fulvestrant vs fulvestrant alone | progression or death (progression free survival PFS) by 58% (fully demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
death (overall survival) | no data | progression or death (progression free survival PFS) | 0.42 [0.32 0.56] | p=0.04 | 0 | 521 | 1 | PALOMA 3, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
palbociclib + letrozole vs letrozole alone | progression or death (progression free survival PFS) by 44% (fully demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
death (overall survival) | no data | progression or death (progression free survival PFS) | 0.56 [0.46 0.68] | p=0.04 | 0 | 815 | 2 | PALOMA-2,PALOMA 1/TRIO-18, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |